Clinical Trial Update: Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the combination of gemcitabine, docetaxel, and cetuximab in patients with unresectable advanced non-small cell lung cancer; the trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERBITUX (cetuximab)
• Gemzar (gemcitabine)
• Taxotere (docetaxel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-11-13